drugset / Trial / NCT01659138
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis
RandomizedParallel-groupDouble-blindTreatment
Summary
Primary Objective: To assess the efficacy of SAR339658 Secondary Objective: To assess the safety of SAR339658
Timeline
- Start
- 2012-08
- Primary completion
- 2014-06
- Completion
- 2016-04
Outcome
Outcome not reported
Stopped (Enrollment): “Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vatelizumab | Monoclonal antibody | — | Intravenous |